The biotech company previously
Immunicum AB Company Announcement Immunicum has received approval to extend the phase I/II-study in liver cancer by up to six patients to be treated with INTUVAX in combination with first-line tre. Att ett bolag medverkar
Immunicum AB Company Announcement Immunicum gives a status update from the ongoing phase II study (MERECA) in metastatic kidney cancer and reports significantly simplified vaccine cell handling G. Aktiespararna Stora Aktiedagen Stockholm
Press Release Stockholm, Sweden, December 21, Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Immunicum Publishes Year-End Letter by CEO and Announces Upcoming Shareholder Event to Present Pipeline Outlook | Analysguiden - Analys, Börs, Bolagsfakta - användbart verktyg för investerare. 
Immunicums investerarmöte i Stockholm Tid:
Press Release. 18 November Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Cancer Immunotherapies-- Synergistic combination of each company’s unique approach and joint expertise in allogeneic dendritic cell biology Immunicum AB (publ; ) meddelar
Christine Lind was appointed interim chairman and Dharminder Chahal and Andrea van Elsas were elected as new members of Immunicum’s Board of Directors. Immunicum received Orphan Drug Designation for ilixadencel as a treatment of soft tissue sarcoma, including gastrointestinal stromal tumors (GIST), from the FDA and as a treatment of GIST from.
I samband med nyemissionerna kommer
Press Release. 19 April Immunicum Announces Presentations at Upcoming Scientific Conferences in April and May. Immunicum AB (publ) today announced that it will participate and deliver multiple presentations featuring its proprietary Phase II clinical candidates, immune primer ilixadencel and cancer relapse vaccine DCP, at the following upcoming scientific conferences.
Mendus is listed on NASDAQ
With respect to the planned change of market place of trading from Nasdaq First North Premier to Nasdaq OMX main list, Immunicum AB's Board of Directors has resolved to change the dates for publishing the Company's Year-end report /, Annual. · · Hitta Artiklar
Several lines of evidence support immunotherapy in hepatocellular carcinoma (HCC). We have shown that intratumoral injections of the immune primer ilixadencel (pro-inflammatory allogeneic dendritic cells) are safe in renal-cell carcinoma. Here, we assessed ilixadencel as a single agent and combined .